Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer

The skeletal muscle index (SMI), which is calculated as the ratio of skeletal muscle area at the third lumbar vertebral level divided by height squared, has been considered a prognostic factor in patients with breast cancer.